Blog | Skyhawk Therapeutics

Careers

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that...

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

May 12, 2020 08:37 AM EDT Amber Tong – Senior Editor Early collaborations with big-name partners lent Skyhawk Therapeutics both...

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

by Ben Adams Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also...

The 20 under 40 : Inside the next generation of biopharma leaders

Inside the next generation of biopharma leaders – Endpoints News “Each generation needs a new music,” Francis Crick wrote in 1988,...

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer at Skyhawk Therapeutics Dr. Terrance Connolly...

The 20 Startups to Watch in Boston in 2020

Welcome to the end of the 2010s. It has been an eventful decade, but even this year alone has been one filled with ups and downs in the...

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

John Carroll – Editor & Founder With Bristol-Myers Squibb’s Celgene buyout all but complete, the BD teams are working in perfect...

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve....

C&EN’s 2019 10 Start-Ups to Watch

by Melody M. Bomgardner Even the hippest chemist doesn’t know how many potentially world-changing chemistry start-ups are out there. As...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to ...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules...

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster of partners out to drug RNA John Carroll – Editor...

Bill Haney’s Skyhawk spears another marquee alliance for its work drugging RNA in Takeda neuro pact

John Carroll – Editor & Founder Bill Haney’s Skyhawk Therapeutics has scored another high-profile development partner. Coming...

Skyhawk News